Molecular genetics diagnostic firm Mainz Biomed N.V. entered a strategic partnership with Ärztliches Labor Dr. Buhlmann with an objective to extend its strengthened position in the German market.
The company specializing in the early detection of cancer said this collaboration grants Mainz Biomed provides wider access as well as the potential for further expansion into Germany’s private health insurance segment where ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer, already receives reimbursement.
Ärztliches Labor Dr. Buhlmann, first established by Dr. Annette Buhlmann in 2006, provides various services including molecular diagnostics, genetics, HLA testing, and infectious disease assessments, catering to a diverse clientele spanning statutory and private insurance segments.
Darin Leigh, Mainz Biomed’s chief commercial officer said, “Partnering with Dr. Buhlmann’s laboratory not only has the potential to further expedite the adoption of ColoAlert in Germany, but also aligns with our core mission of facilitating early CRC detection globally.”
Mainz Biomed said that with about 10.5% of Germany’s population, covered by private health insurance, the partnership is expected to expand a strong market channel for the company.
